Cooperative Agreement NU51IP000333

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding a $146,922 research study at Emory University to investigate factors that influence the efficiency of influenza A virus infection. The study aims to examine how the mode of virus exposure (direct vs. airborne) and environmental conditions such as temperature and humidity impact host immune responses and the...

This $2,074,701 federal Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports a multi-year research program at Emory University focused on understanding the fundamental biological and physical processes that drive influenza A virus transmission in humans. The key objectives of the research program are to: 1) Define the dynamics of viral load, immune...

This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,171,832 to Emory University to conduct research on influenza immune responses. The project aims to leverage systems biology approaches, including multi-omic analyses and machine learning models, to identify novel correlates of protection against influenza beyond neutralizing antibodies. The research will...

This $183,541 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund an investigation into within-household transmission of influenza in low-resource settings. The project aims to quantify the spread of influenza within households and develop a model to assess the effectiveness of interventions like vaccination and masking in mitigating intra-household transmission. The...

This $792,687 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to define the structural features of sialoglycans necessary for influenza virus infection and adaptation across different host species. The primary awardee, the University of Iowa, will utilize CRISPR/Cas9 technology to investigate how the sialoglycan repertoire on human lung cells impacts the replication of influenza...

This Cooperative Agreement award, valued at $3,200,000.00 and funded by the Centers for Disease Control and Prevention (CDC) through the Emerging Infections Programs (CFDA 93.317), supports the development and maintenance of a nationwide cohort of blood donors to estimate the burden of respiratory viruses and characterize associated immune responses. The primary awardee, Vitalant Research Institute (VRI), will lead this multi-year project in collaboration with Westat, Inc. and the American Red...

The federal Cooperative Agreement award U01IP001257, valued at $19,786,074.00 and awarded by the National Center for Immunization and Respiratory Diseases (NCIRD) of the Centers for Disease Control and Prevention (CDC), will fund a 5-year prospective observational study of respiratory virus epidemiology in the greater Boston area. This grant is awarded under the CDC's Public Health Emergency Response: Cooperative Agreement for Emergency Response (CFDA 93.354) program, which supports state,...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,352,292 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois. The purpose of the award is to conduct high-resolution profiling and computational modeling of influenza virus-immune dynamics during natural infection. The research aims to identify reliable immune correlates of reduced viral shedding and transmission risk, as well as define how...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $352,440 to discover human leukocyte antigen (HLA) T cell epitopes in the human metapneumovirus (HMPV). HMPV is a leading cause of lower respiratory infections globally, and this research aims to characterize the human T cell immune response to HMPV to inform safe and effective vaccine development. The project will use...

The federal Cooperative Agreement award U01IP001238, "PREVENT: PREPAREDNESS THROUGH RESPIRATORY VIRUS EPIDEMIOLOGY AND COMMUNITY ENGAGEMENT," was awarded by the National Center for Immunization and Respiratory Diseases (a part of the Centers for Disease Control and Prevention) under the Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention program (CFDA 93.326). The $9,006,864.00 award, with a performance period from August 1, 2024...